Zioptan (tafluprost) / Santen, Merck (MSD) - LARVOL DELTA

The Effect of Preoperative Use of High- vs. Low-PAP-Inducing-Potential FP Agonists on the Surgical Outcomes of Trabeculectomy and AGV Implantation. (PubMed, J Clin Med) - "The eyes were stratified by preoperative FP agonist use into the high-PAP-inducing-potential (bimatoprost or travoprost) and low-PAP-inducing-potential (latanoprost or tafluprost) groups. Although the effect on AGV implantation appears limited, it may still influence early postoperative results. These findings underscore the need to consider PAP risk and medication history when selecting surgical procedures for glaucoma."

Journal • Glaucoma • Ophthalmology

Pseudoexfoliation Glaucoma Selective Laser for Trabeculoplasty Treatment in Vietnam. (PubMed, Endocr Metab Immune Disord Drug Targets) - "SLT can be effectively used as a primary treatment for PXG. In cases of recurrent IOP elevation, a second SLT procedure can be administered alone or in combination with other medications."

Journal • Glaucoma • Ophthalmology

assessment of the role of patch testing in diagnosing allergic contact dermatitis linked to ophthalmic products: a retrospective review of 28 patients (EADV 2025) - "These included one positive result each to latanoprost, tafluprost, polymyxin B, and a hydrating product (Parpadual® gel-cream). Identification of the allergen is the cornerstone of treatment for allergic contact dermatitis related to ophthalmic products. However, in these patients, performing diagnostic patch testing can be challenging due to the lack of individual test substances and potential confounding factors such as cosmetic products, airborne allergens, and the pharmacological vehicle. The literature highlights the need to standardize and enhance the sensitivity of patch testing in ophthalmology; our case series supports this observation, as we found relevant positive results in only 14% of the patients studied (4 out of 28)"

Retrospective data • Review • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Ophthalmology

Efficacy and safety of prostaglandin drugs for elevated intraocular pressure: a Bayesian network meta-analysis. (PubMed, Front Med (Lausanne)) - "To evaluate and compare the effectiveness and safety of latanoprost, bimatoprost, travoprost, and tafluprost in lowering intraocular pressure (IOP) in individuals with glaucoma or ocular hypertension. Latanoprost and tafluprost offered balanced efficacy with better tolerability, making them suitable for patients with mild disease. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251034803."

Journal • Retrospective data • Review • Cardiovascular • Glaucoma • Ophthalmology

A study of the efficacy and treatment adherence of preservative-free tafluprost based on an electronic patient reporting system (ChiCTR) - P=N/A | N=60 | Completed | Sponsor: Changsha Aier Eye Hospital; Changsha Aier Eye Hospital

New trial • Glaucoma • Ophthalmology

Incidence of and factors associated with brimonidine allergy. (PubMed, PLoS One) - "Approximately 5.5% of brimonidine users developed brimonidine allergy, which typically manifested at 32 weeks. Concurrent artificial tear and tafluprost use increased brimonidine allergy risk, whereas topical steroids' concomitant use reduced the risk."

Journal • Retrospective data • Allergy • Immunology

HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation. (PubMed, J Pharm Biomed Anal) - "Some prostaglandin F2α (PGF2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF2α analogs."

Journal

ENDOSafe: Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (clinicaltrials.gov) - P3 | N=80 | Completed | Sponsor: Universitas Diponegoro | Recruiting ➔ Completed | Trial completion date: Apr 2024 ➔ Nov 2024 | Trial primary completion date: Mar 2024 ➔ Aug 2024

Surgery • Trial completion • Trial completion date • Trial primary completion date • Endometriosis • Gynecology • Women's Health • TNFA

Changes in prostaglandin-associated periorbital syndrome: a self-controlled and prospective study. (PubMed, Cutan Ocul Toxicol) - P4 | "Bilateral instillation of bimatoprost, travoprost, latanoprost, or tafluprost was conducted (treatment, 3-6 months). Bimatoprost caused the most severe PAPS, and latanoprost caused the least severe PAPS. The study was registered at www.chictr.org.cn on 15 April 2021, under the identifier ChiCTR2100045465."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Green extraction of prostaglandin analogs in cosmetics using deep eutectic solvents and detection via LC-MS/MS. (PubMed, J Chromatogr A) - "Prostaglandin analogs (bimatoprost, travoprost, tafluprost, etc.) have similar effects to prostaglandins and are effective drugs for treating glaucoma. Additionally, using the Analytical GREEnness calculator and complex green analytical procedure index tools, we confirmed that the method using the DES was greener than the other methods. In this study, we developed an analytical method for illicit compounds contained in eyelash growth serums, offering an eco-friendly approach for the prevention of the distribution of illegal cosmetics."

Journal • Dry Eye Disease • Glaucoma • Ophthalmology

RTA408 alleviates retinal ganglion cells damage in mouse glaucoma by inhibiting excessive autophagy. (PubMed, PLoS One) - "Autophagy mediates the occurrence of glaucoma in mice, promoting RGC apoptosis. RTA408 alleviates RGCs damage by inhibiting excessive autophagy in the context of glaucoma."

Journal • Preclinical • Glaucoma • Ophthalmology

Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database. (PubMed, Ther Adv Drug Saf) - "We screened and analyzed the generic and brand names of latanoprost, bimatoprost, travoprost, and tafluprost in the FAERS database and summarized and cleaned the baseline information of subjects receiving the above-mentioned drugs. Although signal detection analysis based on the FAERS database cannot establish a definitive causal relationship, our study found that FP receptor agonists used in glaucoma can cause various adverse events. Assessing their clinical suitability and potential side effects is crucial for providing personalized treatment and ensuring medication safety."

Adverse events • Journal • Glaucoma • Immunology • Ophthalmology

Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database. (PubMed, BMJ Open Ophthalmol) - "Our findings have revealed a potential relationship due to the biological plausibility among malignant mediastinal neoplasm, full blood count abnormal, blood immunoglobulin E increased, diabetes mellitus, blepharospasm, cataracts, chest discomfort and dry mouth; therefore, it is relevant to continue investigating the possible drug-event association, whether to refute the safety signal or identify a new risk."

Adverse events • Journal • Cataract • CNS Disorders • Diabetes • Glaucoma • Metabolic Disorders • Oncology • Ophthalmology • Xerostomia

Photocrosslinkable Sericin Hydrogel Injected into the Anterior Chamber of Mice with Chronic Ocular Hypertension Efficacy, Medication Sensitivity, and Material Safety. (PubMed, Bioengineering (Basel)) - "Two common drugs (tafluprost eye drops and timolol eye drops) were provided for one week after four weeks of stable IOP, and IOP changes were assessed to determine the drug sensitivity of the mouse model of chronic ocular hypertension...The model can simulate the structural and functional changes of glaucoma and can effectively reduce IOP after the action of most antihypertensive drugs, and it is highly sensitive to drugs. Sericin has no obvious toxic effect on cells and has high safety."

Journal • Preclinical • Cardiovascular • Cataract • Glaucoma • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparing the tolerability of preservative-free tafluprost versus preserved latanoprost in the management of glaucoma and ocular hypertension - an observer blinded active-control trial. (PubMed, Ir J Med Sci) - "Preservative-free and benzalkonium chloride-containing drops were found to be equally effective in lowering IOP with no significant difference in either subjective or objective measurements of dry eye severity."

Journal • Cardiovascular • Dry Eye Disease • Glaucoma • Ophthalmology

Synthetic peptide hydrogel-based human in vitro corneal model (ARVO 2024) - "Cytotoxicity of benzalkonium chloride (BAK) and prostaglandin analogs, bimatoprost, latanoprost, tafluprost and travoprost (50 mM), were assessed using PrestoBlue and lactate dehydrogenase release assays. We provide evidence that the HCE-T cells grown on human collagen-mimetic peptide hydrogels that mimic the stroma is suitable as a corneal in vitro model. The model is convenient for the assessment of cytotoxicity and permeability of ophthalmic drugs in the preclinical phase of drug development"

Preclinical • Glaucoma • Ophthalmology

Efficacy of preserved Tafluprost 0.0015% in lowering intraocular pressure. (PubMed, Indian J Ophthalmol) - "We show significant IOP reduction with preserved tafluprost 0.0015% in a real-world setting. As first-line monotherapy in patients with OHT and in POAG-naïve patients, preserved tafluprost 0.0015% significantly reduced IOP at 3 months. Even as second-line therapy in nonresponders (POAG-Switched) to various drugs (same class [PGAs] versus different class), treatment with preserved tafluprost 0.0015% resulted in significant IOP reduction at 3 months."

Journal • Cardiovascular • Glaucoma • Ophthalmology

ENDOSafe: Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Universitas Diponegoro

New P3 trial • Endometriosis • Gynecology • Women's Health • TNFA

Tafluprost promotes axon regeneration after optic nerve crush via Zn-mTOR pathway. (PubMed, Neuropharmacology) - "Our results suggest that Tafluprost promoted axon regeneration via regulation of the Zn-mTOR pathway, and provide novel research directions for glaucomatous optic nerve injury mechanisms."

Journal • Cholera • Glaucoma • Ophthalmology • BECN1 • IL1B • TNFA

Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells. (PubMed, J Optom) - "BAK-preserved PGA eye drops were more cytotoxic to GCs than PQ-preserved and PF PGA eye drops. BAK-preserved latanoprost induced an inflammatory response in GC. Treatment with PF and PQ-preserved PGA eye drops could mean better tolerability and adherence in glaucoma patients compared to treatment with BAK-preserved PGA eye drops."

Journal • Glaucoma • Inflammation • Ocular Inflammation • Ophthalmology • CXCL8 • IL6

Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease-a randomized controlled trial. (PubMed, Eye (Lond)) - "Changing from preserved to PF glaucoma medications improves ocular surface health and IOP control. Topical cyclosporine 0.1% further reverses GTR-OSD."

Journal • Glaucoma • Ophthalmology • MMP9

WITHDRAWN_Topical Glaucoma Eye Drop Therapy Predicts Decreased Corneal Endothelial Density (ARVO 2023) - "Glaucoma eye drops were classified into the following categories: prostaglandin analogs (latanoprost, latanoprostene bunod, travoprost, tafluprost, bimatoprost, prednisolone) alpha agonists (brimonidine), beta blockers (timolol), carbonic anhydrase inhibitors (dorzolamide, brinzolamide), and Rho kinase inhibitors (netarsudil). As virtually all glaucoma patients take eye drop medications, our findings have major implications for the clinical management of glaucoma. Understanding the specific glaucoma eye drop classes that harm the cornea could lead to the development of treatments that are safer for the rest of the eye."

Corneal Abrasion • Glaucoma • Ophthalmology

FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma. (PubMed, Exp Eye Res) - "FPAs, such as latanoprost, travoprost, bimatoprost, and tafluprost, powerfully lower and control intraocular pressure (IOP), and became first-line therapeutics to treat this leading cause of blindness in the late 1990s to early 2000s. More recently, a latanoprost-nitric oxide (NO) donor conjugate, latanoprostene bunod, and a novel FP/EP3 receptor dual agonist, sepetaprost (ONO-9054 or DE-126), have also demonstrated robust IOP-reducing activity. Moreover, a selective non-PG prostanoid EP2 receptor agonist, omidenepag isopropyl (OMDI), was discovered, characterized, and has been approved in the United States, Japan and several other Asian countries for treating OHT/glaucoma...This has successfully been achieved by the recent approval and introduction of miniature devices into the anterior chamber by minimally invasive glaucoma surgeries. This review covers the three major aspects mentioned above to highlight the etiology of OHT/glaucoma, and the pharmacotherapeutics and..."

Journal • Review • Cardiovascular • Glaucoma • Ophthalmology • PTGER2

The evaluation of the effect of tafluprost on the intraocular pressure of healthy male guinea pigs under different light-and-darkness regimes. (PubMed, Vet Med Sci) - "It is suggested that the variations of IOP in different light/dark conditions be taken into consideration when applying ocular hypotensive agents on guinea pigs' eyes."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study. (PubMed, Int J Ophthalmol) - "Tafluprost is safe for POAG and OH, and tolerable when combined with other eye drops and under various clinical circumstances."

Journal • Observational data • P4 data • Cardiovascular • Glaucoma • Ophthalmology